Q2 2026 Medipharm Labs Corp Earnings Call Transcript
Key Points
- Achieved first positive net income since 2019 and second consecutive quarter of positive adjusted EBITDA, with Q2 EBITDA of $0.9 million, the strongest since 2019.
- Gross margin expanded to 43%, among the highest in recent quarters, driven by disciplined product mix management and branded international sales.
- International medical revenue grew 26% sequentially, with Germany up 45% and branded product sales more than doubling, reducing exposure to spot price volatility.
- Positive Phase II Libby clinical trial results met primary and all key secondary endpoints, validating the pharmaceutical platform and supporting two U.S. provisional patent filings.
- Strong balance sheet with $9.9 million in cash, virtually no debt, and outright ownership of two licensed facilities appraised at over $15 million, providing flexibility for M&A and growth.
- Canadian medical revenue declined to $2.3 million from $3.0 million in Q1, impacted by Veterans Affairs Canada reimbursement changes that reduced the maximum reimbursable amount by 30%.
- Increased competition in Germany is creating pricing pressure, which could challenge sustained growth in that key market.
- Regulatory scrutiny in Germany, particularly around GMP supply chain compliance, may increase operational complexity and costs.
- Revenue of $10 million remains modest, and the company faces ongoing headwinds from shifting pricing, prescribing behavior, and reimbursement regimes across markets.
- The Libby trial results are early-stage, and additional clinical development and regulatory work are required before any commercial pharmaceutical opportunity can be realized.
Thank you for standing by and welcome to the Medipharm Labs conference call to discuss the company's 2026 Q2 results. Our speaker on today's call is Greg Hunter, Interim CEO and Chief Financial Officer.
(Operator Instructions)
After management's presentation, we will take written questions through the Q&A feature on the webcast. The information during this call should be considered together with the more detailed information, disclosure, financial data, and statements available on the company's website and on its CDAR profile at cdarplus.ca. As set out on the webcast slide, I would like to note that remarks during our next call may contain forward-looking information and forward-looking statements within the meanings of applicable securities laws. This includes, without limitation, statements about Medipharm Labs and its current and future plans, expectations, intentions, financial results, operations, levels of activity, performance, goals, or achievements and other future events, trends, profitability, business growth, or development.
All statements other than statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
